Best M P, Boyd S P, Danesi P
Brisbane Veterinary Specialist Centre, Albany Creek, Queensland, Australia.
QML Vetnostics, Murrarie, Queensland, Australia.
Aust Vet J. 2019 May;97(5):162-165. doi: 10.1111/avj.12805.
A 7-year-old female-neutered Maltese Terrier × Papillon dog was presented with tachypnoea and weight loss following 12 months of therapy with toceranib phosphate for a metastatic, histologically-low-grade mast cell tumour. The dog was diagnosed with Pneumocystis canis based on PCR with supportive clinical, radiographic and cytological findings. No other clinical evidence of immunocompromise was identified through assessment of haematology and immunoglobulin quantification. Clinical signs completely resolved with a short course of potentiated sulfonamides and discontinuation of the toceranib.
To the authors' knowledge this represents the first case of Pneumocystis in a dog secondary to immunomodulatory drug therapy. It is also the first case of opportunist infection secondary to a tyrosine kinase inhibitor in dogs.
一只7岁已绝育的马尔济斯犬×蝴蝶犬杂交母犬，因转移性、组织学低级别肥大细胞瘤接受磷酸托西拉尼治疗12个月后出现呼吸急促和体重减轻。基于聚合酶链反应（PCR），结合支持性的临床、放射学和细胞学检查结果，该犬被诊断为犬肺孢子虫感染。通过血液学评估和免疫球蛋白定量分析，未发现其他免疫功能低下的临床证据。短期使用增效磺胺类药物并停用磷酸托西拉尼后，临床症状完全缓解。
据作者所知，这是首例因免疫调节药物治疗继发犬肺孢子虫感染的病例。这也是首例犬因酪氨酸激酶抑制剂继发机会性感染的病例。
